CD79A and COVID-19: The data confirm that the COVID-19 patients had high IgA and IgG cross-reacting antibody responses among the Wuhan strain as well as the Alpha and Delta variants, but not the Omicron variant, and these antibodies showed low cross-reactivities with the S RBD of the Omicron variant.